Inventor · disambiguated record
Matthew Cooper
Also filed as: COOPER MATTHEW · COOPER MATTHEW A · COOPER MATTHEW ALLISTER · COOPER MATTHEW T
27 granted patents·36 pending applications·78 citations·filing 2001–2024
94Inventor score
Top patents by PatentIndex Score
63 records- 0194US10538487B2Sulfonylureas and related compounds and use of sameUNIV QUEENSLAND·Filed 2016·Granted Jan 21, 2020·26 cites·34 claims
- 0293US11130731B2Sulfonylureas and related compounds and use of sameUNIV QUEENSLAND·Filed 2019·Granted Sep 28, 2021·11 cites·43 claims
- 0391US11981667B2Sulfonamide carboxamide compoundsINFLAZOME LTD·Filed 2022·Granted May 14, 2024·1 cites·8 claims
- 0490US11370776B2Sulfonylureas and sulfonylthioureas as NLRP3 inhibitorsINFLAZOME LTD·Filed 2018·Granted Jun 28, 2022·6 cites·19 claims
- 0587US7078380B2Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elementsADPROTECH LTD·Filed 2001·Granted Jul 18, 2006·21 cites·12 claims
- 0683US11465992B2Sulfonamide carboxamide compoundsINFLAZOME LTD·Filed 2018·Granted Oct 11, 2022·1 cites·37 claims
- 0781US11613542B2Sulfonylureas and sulfonylthioureas as NLRP3 inhibitorsINFLAZOME LTD·Filed 2018·Granted Mar 28, 2023·2 cites·32 claims
- 0880US11834433B2CompoundsINFLAZOME LTD·Filed 2019·Granted Dec 5, 2023·2 cites·19 claims
- 0980US11542255B2Sulfonylureas and sulfonylthioureas as NLRP3 inhibitorsINFLAZOME LTD·Filed 2018·Granted Jan 3, 2023·2 cites·24 claims
- 1080US2024400502A1Sulfonylureas and related compounds and use of sameUNIV QUEENSLAND·Filed 2023·Application pending·0 cites
- 1179US11858922B2Sulfonylureas and related compounds and use of sameUNIV QUEENSLAND·Filed 2017·Granted Jan 2, 2024·2 cites·36 claims
- 1279US11434190B2Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseasesUNIV QUEENSLAND·Filed 2017·Granted Sep 6, 2022·2 cites·15 claims
- 1379US2025115591A1Novel sulfonamide carboxamide compoundsINFLAZOME LTD·Filed 2024·Application pending·0 cites
- 1477US2025082785A1Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptorsWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 1576US11926600B2Sulfonylureas and sulfonylthioureas as NLRP3 inhibitorsINFLAZOME LTD·Filed 2018·Granted Mar 12, 2024·1 cites·12 claims
- 1675US2025019355A1CompoundsINFLAZOME LTD·Filed 2024·Application pending·0 cites
- 1774US12410116B2Compounds and use thereof in methods of treatmentUNIV QUEENSLAND·Filed 2023·Granted Sep 9, 2025·0 cites·17 claims
- 1873US2025101099A1Chimeric antigen receptor t cells (car-t) for the treatment of cancerWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 1972US2025043243A1Methods for genome-editing and activation of cellsWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 2071US12304941B2Suppression of cytokine release syndrome in chimeric antigen receptor cell therapyWASHINGTON UNIVERSITY ST LOUIS·Filed 2022·Granted May 20, 2025·0 cites·15 claims
- 2170US2024150428A1Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignanciesWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 2270US2022112159A1Sulfonylureas and related compounds and use of sameUNIV QUEENSLAND·Filed 2021·Application pending·0 cites
- 2369US2024374639A1Expansion of memory natural killer cellsWUGEN INC·Filed 2024·Application pending·0 cites
- 2466US2024189355A1Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of useWUGEN INC·Filed 2023·Application pending·0 cites
- 2565US2023100768A1Inhibitors of sox18 protein activity for treating angiogenesis and/or lymphangiogenesis-related diseasesUNIV QUEENSLAND·Filed 2022·Application pending·0 cites
- 2665US2024173407A1Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agentsWUGEN INC·Filed 2023·Application pending·0 cites
- 2764US10280197B2Discovery of the first selective C5A receptor 2 (C5L2/C5AR2) ligandsUNIV CALIFORNIA·Filed 2016·Granted May 7, 2019·1 cites·12 claims
- 2864US2021332020A1Phenylsulfonylurea derivatives useful as nlrp3 inhibitorsINFLAZOME LTD·Filed 2019·Application pending·0 cites
- 2964US2024075141A1Chimeric receptor constructs for nk cellsWUGEN INC·Filed 2023·Application pending·0 cites
- 3063US2024033357A1Chimeric antigen receptors and uses thereofWUGEN INC·Filed 2023·Application pending·0 cites
- 3160US2023330228A1Hybrid promoters, vectors containing same and methods of useWUGEN INC·Filed 2023·Application pending·0 cites
- 3258US2020054675A1Suppression of cytokine release syndrome in chimeric antigen receptor cell therapyUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 3356US12350349B2Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptorsDIPERSIO JOHN F·Filed 2017·Granted Jul 8, 2025·0 cites·31 claims
- 3456US2020040056A1Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignanciesUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 3556US2020109364A1Methods for genome-editing and activation of cellsUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 3654US2020071397A1Chimeric antigen receptor t cells (car-t) for the treatment of cancerUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 3752US12187702B2Sulfonamideurea compoundsINFLAZOME LTD·Filed 2019·Granted Jan 7, 2025·0 cites·8 claims
- 3852US11884645B2Sulfonyl acetamides as NLRP3 inhibitorsINFLAZOME LTD·Filed 2019·Granted Jan 30, 2024·0 cites·20 claims
- 3952US2022401414A1Treatment and prevention of a neurodegenerative disorderINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4052US2022389031A1Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitorsINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4152US2022395490A1Treatment of arthritisINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4251US12221434B2Sulfonamide carboxamide compoundsINFLAZOME LTD·Filed 2018·Granted Feb 11, 2025·0 cites·19 claims
- 4351US2022409586A1Treatment and prevention of neuroinflammation or an inflammatory brain disorderINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4451US2022409585A1Treatment of autoinflammatory disordersINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4550US12168653B2Sulfonamide derivates as NLRP3 inhibitorsINFLAZOME LTD·Filed 2019·Granted Dec 17, 2024·0 cites·18 claims
- 4650US11530200B2CompoundsINFLAZOME LTD·Filed 2019·Granted Dec 20, 2022·0 cites·18 claims
- 4750US2022163539A1Nlrp3 inflammasome inhibitionINFLAZOME LTD·Filed 2020·Application pending·0 cites
- 4850US2023121952A1CompoundsINFLAZOME LTD·Filed 2021·Application pending·0 cites
- 4949US2023210952A1Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cellsWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Application pending·0 cites
- 5048US2022289766A1Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitorsINFLAZOME LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Matthew Cooper files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →